Quality Improvement in Cytology Where Do We Go From Here?

被引:3
|
作者
Renshaw, Andrew A. [1 ]
机构
[1] Baptist Hosp Miami, Dept Pathol, Miami, FL 33176 USA
关键词
URINE CYTOLOGY; UROVYSION; MALIGNANCY; RISK; CYTOTECHNOLOGISTS; PERFORMANCE; SYSTEM;
D O I
10.5858/arpa.2010-0606-RA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Cytology is a success because of the many quality controls used to ensure the accuracy of its results. Nevertheless, additional information is becoming available to the cytologist, often from untraditional sources, and the best way to use that information to improve the quality of cytology is not yet known. Objective.-To review ways to use new information to improve the quality of cytology. Data Sources.-Review of relevant literature. Results.-Information contained in many sources can be used in new ways to improve the quality of cytology. These include the timing of cytologic and histologic correlation, electronic medical records, workload information, prior aspirations, and molecular tests. Conclusions.-To maintain their high standard of excellence, cytologists should seek to define the most appropriate way to incorporate this new information into their interpretation of individual cases. (Arch Pathol Lab Med. 2011;135:1387-1390; doi:10.5858/arpa.2010-0606-RA)
引用
收藏
页码:1387 / 1390
页数:4
相关论文
共 50 条
  • [1] Calibration research: where do we go from here?
    Bol, Linda
    Hacker, Douglas J.
    FRONTIERS IN PSYCHOLOGY, 2012, 3
  • [2] Pay communication: Where do we go from here?
    Marasi, Shelly
    Bennett, Rebecca J.
    HUMAN RESOURCE MANAGEMENT REVIEW, 2016, 26 (01) : 50 - 58
  • [3] Audit Committee Research: Where Do We Stand, and Where Do We Go from Here?
    Hermanson, Dana R.
    Hurley, Patrick J.
    Obermire, Kara M.
    AUDITING-A JOURNAL OF PRACTICE & THEORY, 2024, 43 (03): : 165 - 185
  • [4] Inevitable Reckonings, Or, Where Do We Go from Here?
    Karayol, Soykan
    Melo, Carla
    CANADIAN THEATRE REVIEW, 2024, 199/200 : 66 - 74
  • [5] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
    Lippi, Giuseppe
    Plebani, Mario
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
  • [6] Sitting and chronic disease: where do we go from here?
    Wijndaele, Katrien
    Healy, Genevieve N.
    DIABETOLOGIA, 2016, 59 (04) : 688 - 691
  • [7] Early intervention in psoriasis: Where do we go from here?
    Felix, Paulo Antonio Oldani
    Sampaio, Ana Luisa
    Silva, Bruno Leonardo
    Viana, Analia Luiza Porto
    FRONTIERS IN MEDICINE, 2022, 9
  • [8] Psychiatric inpatient care: where do we go from here?
    Samele, C.
    Urquia, N.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2015, 24 (05) : 371 - 375
  • [9] Infertility and Preterm Delivery: What Do We Know and Where Do We Go from Here?
    Wise, Lauren A.
    PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2015, 29 (02) : 97 - 100
  • [10] Antepartum Testing for the Prevention of Stillbirth Where Do We Go From Here?
    Johnson, Grace J.
    Clark, Steven L.
    Turrentine, Mark A.
    OBSTETRICS AND GYNECOLOGY, 2018, 132 (06) : 1407 - 1411